Inmune Bio(DE:0Y2)
€1.390.00 (0.00%)
DE:0Y2
Inmune Bio financials statements
€1.39
At close:0.00 (0.00%)
Inmune Bio (0Y2) Ratios
0 Followers
Inmune Bio Ratios
DE:0Y2's free cash flow for Q3 2026 was $-2.96M. For the 2026 fiscal year, DE:0Y2's free cash flow was increased by $430.00K and operating cash flow was $-3.39M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.55 | 3.14 | 2.16 | 5.92 | 18.95 |
| Quick Ratio | 3.55 | 3.14 | 2.16 | 5.92 | 20.21 |
| Cash Ratio | 2.94 | 2.90 | 1.94 | 4.78 | 17.16 |
| Solvency Ratio | -5.19 | -5.56 | -0.01 | -0.06 | -0.06 |
| Operating Cash Flow Ratio | -2.68 | -4.62 | -0.65 | -2.08 | -6.54 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -1.21 | -4.54 | -395.89 |
| Net Current Asset Value | $ 21.06M | $ 15.20M | $ 21.08M | $ 42.98M | $ 62.89M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.01 | 0.18 | 0.19 | 0.15 |
| Debt-to-Equity Ratio | 0.04 | 0.01 | 0.27 | 0.25 | 0.19 |
| Debt-to-Capital Ratio | 0.04 | 0.01 | 0.21 | 0.20 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.14 | 0.15 |
| Financial Leverage Ratio | 1.38 | 1.23 | 1.49 | 1.36 | 1.25 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.05 | 0.13 | 0.09 |
| Interest Debt Per Share | 0.04 | 0.02 | 0.58 | 0.85 | 0.94 |
| Net Debt to EBITDA | 0.52 | 0.49 | 0.00 | 0.00 | 0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -91866.00% | -300585.71% | -19187.74% | -6938.77% | -16106.63% |
| EBITDA Margin | -91698.00% | -296635.71% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -61738.00% | -304535.71% | -19187.74% | -6938.77% | -16106.63% |
| Pretax Profit Margin | -91866.00% | -300585.71% | -19360.00% | -7299.20% | -16762.43% |
| Net Profit Margin | -91866.00% | -300585.71% | -19360.00% | -7299.20% | -16762.43% |
| Continuous Operations Profit Margin | -91866.00% | -300585.71% | -19360.00% | -7299.20% | -16762.43% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 148.80% | 98.70% | 100.90% | 105.19% | 104.07% |
| Return on Assets (ROA) | -141.98% | -106.37% | -52.64% | -33.37% | -30.36% |
| Return on Equity (ROE) | -195.26% | -131.11% | -78.68% | -45.42% | -37.82% |
| Return on Capital Employed (ROCE) | -128.97% | -131.83% | -77.18% | -36.61% | -30.50% |
| Return on Invested Capital (ROIC) | -125.70% | -131.26% | -61.23% | -34.16% | -30.45% |
| Return on Tangible Assets | -141.98% | -182.58% | -74.12% | -41.82% | -36.37% |
| Earnings Yield | -110.75% | -45.18% | -14.82% | -24.02% | -18.44% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.01 | 0.01 | 0.06 | 0.04 | 0.03 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.05 | 0.05 | 0.37 | 0.74 | 0.25 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Cash Conversion Cycle | 33149.30 | 36734.64 | 5750.52 | 8257.39 | 11099.23 |
| Days of Sales Outstanding | 33149.30 | 36734.64 | 5750.52 | 8257.39 | 11099.23 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 33149.30 | 36734.64 | 5750.52 | 8257.39 | 11099.23 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.85 | -1.67 | -0.67 | -1.27 | -1.77 |
| Free Cash Flow Per Share | -0.89 | -1.67 | -0.67 | -1.27 | -2.70 |
| Dividend Paid and CapEx Coverage Ratio | -21.67 | 0.00 | 0.00 | 0.00 | -1.90 |
| Capital Expenditure Coverage Ratio | -21.67 | 0.00 | 0.00 | 0.00 | -1.90 |
| Operating Cash Flow Coverage Ratio | -21.84 | -86.88 | -1.15 | -1.48 | -1.87 |
| Operating Cash Flow to Sales Ratio | -451.64 | -2382.93 | -77.29 | -60.66 | -157.48 |
| Free Cash Flow Yield | -56.96% | -35.82% | -5.92% | -19.96% | -26.44% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.84 | -2.21 | -6.75 | -4.16 | -5.42 |
| Price-to-Sales (P/S) Ratio | 829.46 | 6652.75 | 1306.23 | 303.90 | 909.04 |
| Price-to-Book (P/B) Ratio | 1.76 | 2.90 | 5.31 | 1.89 | 2.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.76 | -2.79 | -16.90 | -5.01 | -3.78 |
| Price-to-Operating Cash Flow Ratio | -1.84 | -2.79 | -16.90 | -5.01 | -5.77 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | -0.08 | -0.68 | 0.22 | -0.06 |
| Enterprise Value Multiple | -0.39 | -1.75 | 0.00 | 0.00 | 0.00 |
| Enterprise Value | 17.76M | 72.60M | 177.06M | 76.81M | 104.96M |
| EV to EBITDA | -0.39 | -1.75 | 0.00 | 0.00 | 0.00 |
| EV to Sales | 355.12 | 5185.75 | 1142.29 | 205.39 | 579.89 |
| EV to Free Cash Flow | -0.75 | -2.18 | -14.78 | -3.39 | -2.41 |
| EV to Operating Cash Flow | -0.79 | -2.18 | -14.78 | -3.39 | -3.68 |
| Tangible Book Value Per Share | 0.88 | 0.78 | 1.20 | 2.43 | 3.95 |
| Shareholders’ Equity Per Share | 0.88 | 1.61 | 2.12 | 3.35 | 4.97 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 |
| Net Income Per Share | -1.73 | -2.11 | -1.67 | -1.52 | -1.88 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.01 | 1.05 | 1.04 |
| Research & Development to Revenue | 413.18 | 2369.00 | 130.79 | 45.63 | 113.50 |
| SG&A to Revenue | 205.20 | 677.36 | 62.08 | 24.75 | 48.57 |
| Stock-Based Compensation to Revenue | 198.20 | 543.21 | 47.54 | 19.11 | 26.50 |
| Income Quality | 0.49 | 0.79 | 0.40 | 0.83 | 0.94 |
Currency in USD
